Image

Treating Mild Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation

Treating Mild Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation

Recruiting
18-75 years
All
Phase 2

Powered by AI

Overview

The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in military veteran participants with histories of traumatic brain injuries. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.

Description

Using two treatment arms, the study will examine improvement of verbal retrieval and other cognitive deficits associated with remote traumatic brain injury by comparing (1) 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to presupplementary motor area for 20 minutes over 15 sessions to (2) sham tDCS following the same schedule. Additionally, after completing the initial active or sham treatment and 3-month follow-up testing sessions, selected participants will be invited back for newly assigned treatment conditions, 20 minutes over 15 sessions and will be and re-evaluated at 2- and 3-months follow-up testing sessions.

Veterans with histories of traumatic brain injuries and observed cognitive deficits will be randomly assigned to one of the two treatment arms (and re-assigned for the second round of intervention, as described above). Primary outcome verbal retrieval measures, secondary neuropsychological and electroencephalography (EEG) measures, and prescreening assessments for study concussion history and contraindications for treatment will be collected prior to being assigned to a treatment arm (i.e., baseline).

Primary outcome verbal retrieval measures and secondary neuropsychological and electroencephalography (EEG) measures will be collected after treatment sessions 5, 10, and 15 and two times following treatment competition (i.e., 2-months and 3-months). For participants selected for the second round of intervention, primary outcome verbal memory measures and secondary neuropsychological and electroencephalography (EEG) measures will be collected again after treatment sessions 5, 10, and 15 and two times following competition of the second treatment (i.e., 2-months and 3-months).

Eligibility

Inclusion Criteria: Participants are to be between the ages of 18-75, have previously

        served in the US armed services, and have had a traumatic brain injury that has led to a
        verbal retrieval deficit based on neuropsychological testing criteria. Traumatic brain
        injury must be in the mild to moderate range based on evaluation, including, the Ohio State
        TBI Identification Method (administered by our research group). You must be fluent in
        speaking and reading English.
        Exclusion Criteria: Exclusion criteria include a history of a psychological or neurological
        disorder, including, dementia of any type, epilepsy or other seizure disorders, severe
        traumatic brain injury, post-traumatic stress disorder, brain tumor, present drug abuse,
        stroke, blood vessel abnormalities in the brain, Parkinson's disease, Huntington's disease,
        or multiple sclerosis. Additionally, exclusion criteria include inability to give informed
        consent; cranial implants or skull defects that affect tDCS administration; and use of
        medications that interact with or potentially interact with tDCS effects, including,
        anti-convulsants, amphetamines, L-dopa, carbamazepine, sulpiride, pergolide, lorazepam,
        rivastigmine, dextromethorphan, D-cycloserine, flunarizine, ropinirole, or citalopram.

Study details
    Traumatic Brain Injury

NCT04869059

The University of Texas at Dallas

29 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.